2022年11月4日

關於IVERIC bio(公司)未來預期、計劃和前景的任何陳述均構成前瞻性陳述，適用於1995年《私人證券訴訟改革法案》下的安全港條款。前瞻性陳述包括關於公司戰略、運營和未來期望、計劃和前景的陳述，以及任何其他包含“預期”、“相信”、“估計”、“期望”、“打算”、“目標”、“可能”、“計劃”、“預測”、“項目”、“尋求”、“目標”、“潛力”、“將”、“將”、“可能”、“應該”、“繼續”和類似表述的陳述。在本報告中，公司的前瞻性陳述包括公司的gather1和GATHER2臨床試驗評估avacincaptad pegol (ACP或Zimura)治療地理萎縮的重要性和影響，以及ACP的潛在用途。此類前瞻性陳述涉及重大風險和不確定性，可能導致公司的研發計劃、未來結果、業績或成就與前瞻性陳述中表達或暗示的內容顯著不同。這些風險和不確定性包括臨床試驗和其他研發項目的進展和結果，來自科學界和醫學界以及公司競爭對手的發展，以及公司向美國證券交易委員會提交的季度和年度報告中“風險因素”一節中討論的其他因素。任何前瞻性陳述僅代表本公司截至本報告日期的觀點。本公司預計，後續事件和發展可能導致其觀點發生變化。雖然公司可以選擇在未來的某個時候更新這些前瞻性陳述，但公司明確放棄任何義務，除非法律要求這樣做。Avacincaptad Pegol對地理萎縮的療效:GATHER1和GATHER2結果Sunil S Patel，醫學博士，博士; Giovanni Staurenghi, MD3; Ramin Tadayoni, MD, PhD4; Carl J Danzig, MD5; David R Lally, MD6; Anat Loewenstein, MD7; David S Boyer, MD8; Carl D Regillo, MD9; Tien P Wong, MD10; Glenn J Jaffe, MD11; Justin Tang, PhD12; Liansheng Zhu, PhD12; Hersh Patel, OD12;Julie Clark, MD12 1Sierra Eye Associates, Reno, NV, USA; University of Nevada, Reno School of Medicine, Reno, NV, USA. 2West Texas Retina Consultants, Abilene, TX, USA. 3Eye Clinic, Department of Biomedical and Clinical Sciences "Luigi Sacco," University of Milan, Milan, Italy; 4Université de Paris, Ophthalmology Department, AP-HP, Hopital̂ Lariboisière, Paris, France. 5Rand Eye Institute, Deerfield Beach, FL, USA; Florida Atlantic University, Charles E. Schmidt School of Medicine, Boca Raton, FL, USA. 6New England Retina Consultants, Springfield, MA, USA. 7Division of Ophthalmology, Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel. 8Retina Vitreous Associates Medical Group, Los Angeles, CA, USA. 9Wills Eye Hospital, Philadelphia, PA, USA. 10Retina Consultants of Texas; Retina Consultants of America; Blanton Eye Institute, Houston Methodist Hospital, Houston, TX, USA. 11Department of Ophthalmology, Duke University, Durham, NC, USA. 12Iveric Bio, Parsippany, NJ, USA. The Retina Society 55th Annual Scientific Meeting, Pasadena, CA November 2 - 5, 2022 Avacincaptad Pegol is an investigational product that has not been evaluated for safety and efficacy by the FDA © 2022 Iveric Bio. Not for Distribution Disclosures Consultant: Abbvie, Adverum Biotechnologies, AGTC, Alimera Sciences, Allergan, Apellis Pharmaceuticals, Arrowhead, Pharmaceuticals, AsclepiX Therapeutics, Aviceda Therapeutics, Bausch & Lomb , BroadWing Bio, Cholgene Therapeutics, 4D Molecular Therapeutics, Eyepoint Pharmaceuticals, Fronterra Therapeutics, Gemini Pharmaceuticals, Genentech, Graybug Vision, Gyroscope Therapeutics, Iveric Bio, Janssen Pharmaceuticals, Kato Pharmaceuticals, Kartos Therapeutics, Kodiak Sciences, Kriya Therapeutics, Ocular Therapeutix, Oculis, Ocuterra, Opthea, Oxurion, Novartis, Perfuse, PolyPhotonix, Ray Therapeutics, Recens Medical, Regeneron Pharmaceuticals, REGENXBIO, Roche, Stealth Biotherapeutics Therapeutics, Thea Pharma, UNITY Biotechnology, Vanotech Research Support: Adverum Biotechnologies, Annexon Biosciences, Apellis Pharmaceuticals, AsclepiX Therapeutics, 4D Molecular Therapeutics, Gemini Pharmaceuticals, Genentech, Graybug Vision, Gyroscope Therapeutics, Iveric Bio, Janssen Pharmaceuticals, Kodiak, Neurotech, NGM Biopharmaceuticals, Novartis, Ocular Therapeutix, Oculis, Ocuterra, Opthea, Oxurion, Recens Medical, REGENXBIO, Roche, UNITY Biotechnology Speaker: